Search
Respiratory syncytial virus vaccine, adjuvanted
go.drugbank.com/drugs/DB17762ApprovedInvestigationalIt comprises lyophilized recombinant respiratory syncytial virus glycoprotein F (RSVPreF3) stabilized in pre-fusion conformation as the antigen component, which is reconstituted at the time of use with … Arexvy (respiratory syncytial virus vaccine, adjuvanted) is an adjuvanted vaccine developed by GlaxoSmithKline Biologicals.
Flavin mononucleotide
go.drugbank.com/drugs/DB03247ApprovedInvestigational[L54226] In addition to its systemic use as a means of riboflavin supplementation, a topical ophthalmic preparation of FMN was approved by the FDA in October 2025 for use as a photoenhancer in epithelium-on
Doripenem
go.drugbank.com/drugs/DB06211ApprovedWithdrawnThe FDA revised the doripenem label in 2014 to include a warning against use in ventilator-associated pneumonia and to reiterate its safety and efficacy for its approved indications. … Doripenem is a broad-spectrum, carbapenem antibiotic marketed under the brand name Doribax by Janssen.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseAndusomeran
go.drugbank.com/drugs/DB18227ApprovedInvestigationalAndusomeran is a COVID-19 mRNA vaccine developed for use during the 2023-2024 season.[L40074,L48832,L48837] It is similar to previous mRNA vaccines developed by Moderna (e.g. … [elasomeran], [imelasomeran]), but is designed to be effective against the Omicron XBB.1.5 subvariant.
Sarafloxacin
go.drugbank.com/drugs/DB11491ApprovedVet approvedWithdrawnSarafloxacin is a quinolone antibiotic drug, which was discontinued by its manufacturer, Abbott Laboratories, before receiving approval for use in the US or Canada.
Maraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalIt was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. … Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseIopodic acid
go.drugbank.com/drugs/DB09333ApprovedWithdrawnOn September 22, 1981, ipodate was submitted again by the company Schering AG but it is currently under an inactive status.[L1082] … It was developed and filed to the FDA by the company BRACCO. This drug was approved on March 15, 1962 but it is nowadays discontinued from the FDA and Health Canada.
Losartan
go.drugbank.com/drugs/DB00678ApprovedInvestigational[L7423] Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough.
Products: ZYLTAN 50 (Losartan Potassium Tablets USP 50mg)Netupitant
go.drugbank.com/drugs/DB09048ApprovedInvestigationalNetupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy … The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.
Ublituximab
go.drugbank.com/drugs/DB11850ApprovedInvestigational[A241045] In December 2022, ublituximab was approved by the US FDA for the treatment of relapsing forms of multiple sclerosis, becoming the first and only anti-CD20 monoclonal antibody for multiple sclerosis … [A244210, A244215,A241045] Ublituximab was initially developed by LFB Group but was licensed to TG Therapeutics in 2012.